Pembrolizumab in Combination With Erlotinib or Gefitinib as First-Line Therapy for Advanced NSCLC With Sensitizing EGFR Mutation

Anti-EGFR agents are standard treatments for patients with EGFR-mutant advanced NSCLC. The feasibility of combining erlotinib or gefitinib with the anti–programmed death 1 immunotherapy pembrolizumab was evaluated in the phase 1/2 KEYNOTE-021 study (NCT02039674). Adults with previously untreated sta...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of thoracic oncology 2019-03, Vol.14 (3), p.553-559
Hauptverfasser:	Yang, James Chih-Hsin, Gadgeel, Shirish M., Sequist, Lecia VanDam, Wu, Chien-Liang, Papadimitrakopoulou, Vassiliki A., Su, Wu-Chou, Fiore, Joseph, Saraf, Sanatan, Raftopoulos, Harry, Patnaik, Amita
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Antibodies, Monoclonal, Humanized - administration & dosage Antineoplastic Combined Chemotherapy Protocols - therapeutic use Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - genetics Carcinoma, Non-Small-Cell Lung - pathology Cohort Studies Combination therapy ErbB Receptors - genetics Erlotinib Erlotinib Hydrochloride - administration & dosage Female Follow-Up Studies Gefitinib Gefitinib - administration & dosage Humans Lung Neoplasms - drug therapy Lung Neoplasms - genetics Lung Neoplasms - pathology Male Middle Aged Mutation NSCLC Pembrolizumab Prognosis Survival Rate
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!